<DOC>
	<DOCNO>NCT00000645</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) hypericin , define type toxicity may observe , determine dos drug associate improvement virological immunological surrogate marker HIV infection . To determine bioavailability synthetic hypericin give 2 percent benzyl alcohol solution . Hypericin unlike drug presently use treat AIDS patient . Hypericin show anti-HIV activity test tube experiment .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study Synthetic Hypericin HIV-Infected Patients With Less Than 300 CD4 Lymphocytes</brief_title>
	<detailed_description>Hypericin unlike drug presently use treat AIDS patient . Hypericin show anti-HIV activity test tube experiment . Each group eight patient receive give dose hypericin intravenous infusion . Doses give three time per week 8 week . When eight patient dose level enter four eight patient complete 3 week therapy without evidence dose-limiting toxicity , additional patient may begin receive drug next dose level . Concurrently , six patient wll participate oral-dosing bioavailability study . NOTE : The initial study stop secondary MTD reach .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypericin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis Pneumocystis carinii pneumonia ( required patient CD4+ &lt; 200 ) . Symptomatic treatment analgesic , antihistamine , antiemetic , antidiarrheal agent , supportive therapy . Short course ( &lt; 10 day ) ketoconazole fluconazole oral candidiasis acyclovir herpes lesion . Topical medication clotrimazole troche nystatin suspension . Concurrent Treatment : Allowed : Blood transfusion . Patients must HIV infection CD+4 lymphocyte count &lt; 300 cells/mm3 . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude . Kaposi 's sarcoma require systemic therapy . Concurrent Medication : Excluded : Continued use opiates drug know induce photosensitivity . Patients follow exclude : Active chronic opportunistic infection time study entry require curative suppressive therapy . Significant liver disease , orthostatic hypotension , cardiac disease , seizure disorder , lymphoma , hypotension . Prior Medication : Excluded : Zidovudine ( AZT ) , dideoxyinosine ( ddI ) , dideoxycytidine ( ddC ) , interferon , antiretroviral agent immunomodulating drug within 1 month prior study entry . Ribavirin within 3 month study entry . Ganciclovir ( DHPG ) , antimycobacterial drug , MAO inhibitor , hypertensioninducing , nephrotoxic , hepatotoxic drug within 14 day entry . Cytotoxic chemotherapy within 1 month prior study entry . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>